100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Contract Awards
Purchase Order HHSN271201100061P
Award Date
11/19/10
Potential Completion Date
9/30/11
Potential Value
$90K
Overview
Contacts
Activity
1
Transactions
1
Subawards
Opportunity Stack
Similar Awards
Federal Agency
National Institute on Drug Abuse
Awardee
Colosi, Deborah VK5WFMYKVNK7
Ultimate Awardee
Not listed
NAICS Category
541990 - All Other Professional, Scientific, and Technical Services
PSC Category
R499 - Support- Professional: Other
Federal Contract Vehicle
Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Description
TAS::75 0892::TAS -- PROFESSIONAL SERVICE IN SUPPORT OF NIMH'S NEUROAIDS INITITATIVE PROJECT
Posted 11/19/10
5
1
Name
Description
Solicitation Number
FederalAgency
Type
PostedDate
NIMH NeuroAIDS Therapeutic Initiative
Added: Nov 05, 2010 11:16 am The National Institute on Drug Abuse (NIDA), Office of Acquisitions Station Support Simplified Acquisitions Branch on behalf of the National Institute of Mental Health (NIMH) intends to negotiate and award a purchase order, on a non-competitive basis, to Dr. Deborah Ann (Bravo) Colosi, 6218 Wagner Lane, Bethesda, MD 20816, for professional services in support the NIMH's NeuroAIDS Therapeutic Initiative. This acquisition will be made pursuant to the authority of FAR 13.106-1(b)(1). The North American Industry Classification System Code is 541990 and the business size standard is $7.0 million.Therapeutic approaches have realized much success in managing HIV/AIDS, however strategies to prevent or treat the neurological complications that frequently accompany HIV disease have been less successful. This is due to limited availability of drugs across the blood brain barrier, the high degree of toxicity that accompanies long term use of current antiretroviral drugs, and the co-morbid mental health conditions that frequently accompany HIV/CNS disease, such as depression, anxieties, mood disorders, as well as others. While the extreme manifestations of AIDS dementia complex have decreased in frequency, less severe but nevertheless debilitating neurological complications persist. This is particularly important as individuals with HIV are living longer with compromised ability to function, also exacerbated by the normal aging processes in an increasing proportion of this population. The National Institute of Mental Health (NIMH) Center for Mental Health Research on AIDS (CMHRA) proposes to expand the therapeutics program by developing several initiatives to identify new therapeutic targets emerging from basic HIV neuropathogenesis research, and foster the pre-clinical and clinical testing of these drugs tough mechanisms supportive of these approaches. The vendor shall perform the following tasks:1. Develop several funding announcements which are part of an integrated strategy to expand on the development and testing of new therapeutic agents for the prevention and treatment of the neurological consequences of HIV/CNS disease. 2. Respond to writing or report requests from the NIMH Office of Director or other requesters relating to the NeuroAIDS portfolio as needed. This includes, but is not limited to, responding to congressional writing requests from OD relating the NeuroAIDS portfolio and Trans-NIH therapeutic information requests.3. Grant or contract related write-ups as needed. This includes, but is not limited to, scientific justifications for Form 1820, professional services contracts, consultant agreements, administrative supplement justifications, brief summaries of grants marked for interest in preparation for pre-council meetings, concept and Program initiative write-ups. 4. Research, planning, coordination and implementation of Program development, conferences and workshops as needed. These include scientific conferences as well as meetings with multi-site projects (NNTC, CHARTER). The contractor will conduct the background research for these announcements, and consult with the COTR weekly to discuss current scientific approaches, ongoing clinical trials, and optimal strategies that should be incorporated into these announcements. During these meetings, the PO will assess progress and make suggestions. The duration of these meetings with the COTR might last up to 3 hours. In addition, the contractor will assist Program in the implementation and management of the next phase of these contracts with the NNTC.Finally, the contractor will provide technical and scientific assistance to the COTR in management of the applications that arrive in response to the FOAs. This includes assisting in programmatic review of the science proposed in the applications and assisting in the management of the applications which are selected by peer review for funding.Dr. Colosi has more than 5 years experience working as a Senior Research Scientist at Bayer HealthCare Pharmaceuticals. During that time, she participated in all aspects of the process of moving drugs from bench to bedside. This includes developing and overseeing the protocols and strategies for testing and assessing the effectiveness of specific drugs as well as reviewing progress and making recommendations for future work. This experience has given her a good understanding of the science and process necessary to move therapeutic agents from bench to bedside. In addition Dr. Colosi has a strong background in basic science, including biochemistry and virology, as seen by her doctoral and post-doctoral research experience, which is essential to understand the complexities of targeting therapeutic interventions to HIV-mediated cell dysfunction. The Division of AIDS Research currently lacks this expertise in the drug development process and yet the need for a strong programmatic approach to the therapeutics in NeuroAIDS is critical. Dr. Colosi brings scientific and drug-company expertise to this effort, which is currently not available among the program staff of the NIMH-DAR.Dr. Colosi has been researching the current state of therapeutic approaches to managing HIV/CNS disease over the past 12 months and has written an extensive review of this area. In addition, she has convened a meeting with some of the leaders in the field to review our current efforts and develop a set of recommendations for next steps. Given the extent of her knowledge, Dr. Colosi is considered uniquely positioned to move the NIMH's proposed approaches to the next phase. Not only does this initiative require knowledge of the field, but it also requires an understanding of existing programs at NIMH in order to leverage resources and maximize use of limited funds. Dr. Colosi has had past experiences with the workshops that she convened. Dr. Colosi's previous work for the NIMH has been outstanding and her continuation is critical to the development of this important program to improve the lives of individuals living with HIV. It is determined that Dr. Colosi is the only known source qualified to perform the required services. No other sources will satisfy the agency's requirement.The period of performance is to be ten (10) months from date of award. Place of performance is to be at the NIH main campus located in Bethesda, Maryland 20892. This is a fee-for-service type acquisition. This is not a solicitation for competitive quotations. However, interested party may submit a statement of capabilities on or before 1:00 PM E.T., November 19, 2010 to Liem T Nguyen, ln18x@nih.gov. All information furnished must be in writing and must contain sufficient detail to allow the NIDA/NINDS to determine if it can meet the above unique specifications described herein. A determination by the Government not to compete this proposed acquisition based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award from the NIDA vendor must be registered in the Online Representations and Certifications Applications (ORCA) at http://orca.bpn.gov. In addition, vendor must be registered in the Central Contractor Registration (CCR) at www.ccr.gov. Please reference announcement number NOI-1838880 on all correspondence.
NOI-1838880
Department of Health and Human Services National Institutes of Health
Award Notice 1/1
11/5/10, 11:16 AM
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
TAS::75 0892::TAS -- PROFESSIONAL SERVICE IN SUPPORT OF NIMH'S NEUROAIDS INITITATIVE PROJECT
Not listed
$90.0k
11/19/10